Ramelteon - CAS 196597-26-9
Catalog number: B0084-062135
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C16H21NO2
Molecular Weight:
259.34
COA:
Inquire
Targets:
Melatonin Receptor
Description:
Ramelteon has high affinity with recombinant human MT1 and MT2 receptors with pKi of 10.05 and 9.70, respectively.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-062135 50 mg $199 In stock
Bulk Inquiry
Purity:
>98%
Synonyms:
TAK-375; TAK 375; TAK375; Ramelteon. Brand name: Rozerem.
MSDS:
Inquire
InChIKey:
YLXDSYKOBKBWJQ-LBPRGKRZSA-N
InChI:
InChI=1S/C16H21NO2/c1-2-15(18)17-9-7-12-4-3-11-5-6-14-13(16(11)12)8-10-19-14/h5-6,12H,2-4,7-10H2,1H3,(H,17,18)/t12-/m0/s1
Canonical SMILES:
CCC(=O)NCCC1CCC2=C1C3=C(C=C2)OCC3
1. Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine,on the rat sleep–wake cycle architecture
Amandine Descamps & Colette Rousset & Mark Millan & Michael Spedding & Philippe Delagrange & Raymond Cespuglio. Psychopharmacology (2009) 205:93–106
One major structure expressing both MT1 and MT2 receptors is the suprachiasmatic nucleus that participates in the regulation of sleep–wake-function, at least partially via an indirect projection from to the noradrenergic locus coeruleus that controls arousal (Aston-Jones et al. 2001). However, the neuronal substrates underlying the influence of melatoninergic mechanisms upon REM sleep require direct evaluation. Mimicking the modest influence of melatonin upon REM sleep, a mild influence upon REM sleep (albeit limited in magnitude and duration as compared with agomelatine) was also seen with ramelteon, a synthetic and selective MT1 and MT2 receptor agonist used to treat insomnia. This effect, and its modest increase in SWS, corresponds to published data, though it is unclear why the influence of ramelteon and melatonin on SWS sleep and waking differ (Miyamoto et al. 2004; Erman et al. 2006; Borja and Daniel 2006).
2. The effects of acute treatment with ramelteon, triazolam, and placebo on driving performance, cognitive function, and equilibrium function in healthy volunteers
Akemi Miyata & Kunihiro Iwamoto & Naoko Kawano & Kunihiro Kohmura. Psychopharmacology (2015) 232:2127–2137
Unlike the benzodiazepine receptor agonists, ramelteon is one of the novel classes approved by FDA for the treatment of insomnia. Ramelteon, a MT1/MT2 melatonin receptor agonist, shows higher affinities for these receptors than does the natural ligand (Pandi-Perumal et al. 2007). Because ramelteon helps to promote sleep and circadian rhythm entrainment without significant interaction with GABA-benzodiazepine and muscarinic receptors, ramelteon is expected to have minimal effect on sedation and cognitive function. Several lines of evidences showed that ramelteon has no detrimental effects on psychomotor and cognitive performance (Erman et al. 2006; Johnson et al. 2006; Karim et al. 2006; Mayer et al. 2009;Rothetal. 2005; Zammit et al. 2007, 2009a, 2009b), but more recent studies demonstrated that ramelteon significantly impaired psychomotor performance and cognitive function including driving performance (Cohen et al. 2010;Metsetal. 2011). Therefore, the effects of ramelteon on these activities are controversial. The subjects of the studies that showed that ramelteon did not impair performances are substance abusers or insomnia patients, while the subjects of the studies that showed that ramelteon impaired performances are healthy subjects. The difference of the subjects’ characteristics may contribute to these results. Additional investigations are urgently needed to elucidate the effect of ramelteon on functional ability; however, there is little research concerning the effect of ramelteon on daily living including automobile driving. According to the results of the recent studies, we hypothesized that ramelteon would influence cognitive function including driving performance in the healthy subjects.
3. Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea
Meir Kryger & Sherry Wang-Weigand & Thomas Roth. Sleep Breath (2007) 11:159–164
Ramelteon is a nonsedating chronohypnotic indicated for the treatment of insomnia. Unlike benzodiazepine receptor agonists, which act as broad CNS depressants and are sedative, ramelteon is highly selective for MT1 and MT2 receptors, which are located primarily in the suprachiasmatic nucleus of the hypothalamus, and does not produce general sedative effects. In the present study, the safety of ramelteon was evaluated in subjects with mild to moderate obstructive sleep apnea.
4. Effect of Ramelteon, a selective MT1/MT2-receptor agonist, on respiration during sleep inmild tomoderate COPD
Meir Kryger & Sherry Wang-Weigand & Jeffrey Zhang & Thomas Roth. Sleep Breath (2008) 12:243–250
Ramelteon is a novel chronohypnotic used for the treatment of insomnia. The recommended therapeutic dose is 8 mg for adults and older adults. Unlike the hypnotics that act at gamma-aminobutyric acid (GABA)A–benzodiaz-epine receptor complexes located throughout the central nervous system (CNS), ramelteon has a unique mechanism based on a high selectivity for the melatonin MT1 and MT2 receptors located in the suprachiasmatic nucleus (SCN). The SCN is located within the hypothalamus and is known to regulate the body’s circadian rhythms, including the sleep–wake cycle. Studies indicate that the MT1 receptor mediates the acute inhibition of SCN firing by melatonin, and activity at the MT2 receptor has been associated with the phase-shifting effects of melatonin on circadian rhythms. Ramelteon has minimal affinity for the following CNS binding sites: GABA, benzodiazepine, opioid, acetylcholine, histamine, dopamine receptors, and ion channels and transporters. Ramelteon is rapidly absorbed after oral administration, with peak serum concentrations at less than 1 h.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Melatonin Receptor Products


CAS 93515-00-5 2-Iodomelatonin

2-Iodomelatonin
(CAS: 93515-00-5)

2-Iodomelatonin is a potent agonist of the melatonin receptors 1 (MT1) with Ki value of 28 pM. It could be used to identify, characterize and localize melatonin...

CAS 1016-47-3 N-Acetyltryptamine

N-Acetyltryptamine
(CAS: 1016-47-3)

N-Acetyltryptamine is a structural analog of 5-methoxy-N-acetyltryptamine which acts as a melatonin receptor antagonist in chicken retina and frog skin, and as ...

CAS 220339-00-4 DH 97

DH 97
(CAS: 220339-00-4)

DH 97 is a potent MT2 melatonin receptor antagonist (pKi = 8.03) with 89- and 229-fold selectivity over MT1 and GPR50 (melatonin-related orphan receptor) respec...

CAS 80270-68-4 AH 001

AH 001
(CAS: 80270-68-4)

AH 001 is a potent melatonin agonist.

CAS 343263-95-6 DH 97

DH 97
(CAS: 343263-95-6)

DH 97 is a selective MEL-1B-R (melatonin receptor) antagonist.

CAS 151889-03-1 2-Phenylmelatonin

2-Phenylmelatonin
(CAS: 151889-03-1)

2-Phenylmelatonin is an antagonist of the MEL-1A-R, MEL-1B-R, MT3, observed to demonstrate mixed antagonist/agonist activity in systems with differential expres...

CAS 63762-74-3 6-Chloromelatonin

6-Chloromelatonin
(CAS: 63762-74-3)

6-Chloromelatonin is a potent agonist of the melatonin receptors, which is active at nanomolar concentrations. It shows higher affinity for binding to hamster b...

CAS 609799-22-6 Tasimelteon

Tasimelteon
(CAS: 609799-22-6)

Tasimelteon (trade name Hetlioz) is a drug approved by the FDA solely for the treatment of non-24-hour sleep–wake disorder (often designated as N24HSWD) in tota...

Chemical Structure

CAS 196597-26-9 Ramelteon

Quick Inquiry

Verification code

Featured Items